Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of JMT101 plus irinotecan in previously treated advanced colorectal cancer
CTR20253285Phase 3Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Oct 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of becotatug, irinotecan in colorectal cancer (CRC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Oct 2025; status: active.
02
Drugs
becotatugirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20253285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253285.